ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

NCI Role, Issues In Education Considered By DRCCA Board

August 21, 1981

Nexavar Improves PFS In Phase III Trial

January 25, 2013

House Plan Promises $3.5 Billion For NIH; Cooperative Groups May Get AHRQ Funds

January 23, 2009

In Brief: CFO Dwain Morris to Leave MD Anderson Cancer Center

May 2, 2014

Rogers Reaffirms Congress’ Interest In Cancer Program; Act Renewal To “Broaden, Sustain It”

April 14, 1978

In Brief: Tipping Resigns Forom ACS; Vaughan Joins UAB BMT Program; PCI Recruits Ball, Finn, Mirro

September 20, 1991